New pill aims to tame rheumatoid arthritis inflammation

NCT ID NCT07684157

Not yet recruiting Disease control Sponsor: Jacobio Pharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study tests an experimental oral drug called JAB-8263 in adults with active rheumatoid arthritis. The goal is to see if it is safe and can reduce joint inflammation and pain. Participants take the drug or a placebo every other day for 28 days. The trial is small and early-stage, so its main focus is safety and how the body processes the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JAB-8263 (oral drug)
What this could lead to: If successful, JAB-8263 could offer a new oral treatment option for people with active rheumatoid arthritis, potentially reducing joint pain and swelling.
What could go wrong: This is an early Phase IIa study with only 32 participants, so results may not apply to everyone. The drug may cause side effects or prove no better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS (RA)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Beijing Hospital

Beijing, Beijing Municipality, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.